secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001193125-26-127041
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GLOW2 Phase 3 positive: Zenkuda meets primary endpoint, 62.5% vs 3.3% DRSS improvement, BLA accelerated
--------------------------------------------------------------------------------

- 62.5% of Zenkuda patients achieved ≥2-step DRSS improvement vs 3.3% sham (p<0.0001).
- 85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); 13.7% had ≥3-step DRSS improvement vs 0% sham.
- Zenkuda well-tolerated: 0% intraocular inflammation, low cataract rate (2.3% vs 1.6%).
- Efficacy independent of GLP-1 use: 60.0% with GLP-1 vs 64.3% without GLP-1.
- Kodiak intends to accelerate BLA for Zenkuda; KSI-501 (wet AMD) readout 3Q2026, KSI-101 (MESI) 4Q2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/0001193125-26-127041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/d283186d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-127041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer